Assays using lysate reagents prepared from horseshoe crab hemocyte extract (limulus amoebocyte lysate, LAL) are commonly and widely used to detect and measure endotoxin in parenteral drugs and medical devices. However, lysate reagents suffer from lot-to-lot variations leading to possible fluctuations in testing. Also, this continued usage of lysate reagents leads to the possible decline of the horseshoe crab population. Recently, a new recombinant chromogenic reagent, PyroSmart, consisting of three recombinant factors was introduced to the market. There are now three recombinant products; two with recombinant factor C reagents and PyroSmart with the complete recombinant LAL system. We evaluated the applicability of the reagent to the harmonized bacterial endotoxins test in the United States, European and Japanese pharmacopeias. The recombinant product showed equivalent potency of thirteen endotoxins from different bacterial strains to conventional chromogenic lysate reagents as long as their assay modes are identical. All analytical characteristics or assay parameters of the reagent satisfied the acceptance criteria which are set for the use for
INTRODUCTION
Parenteral drugs are strictly managed by pharmacopeias in all regions, including the United States, the European Union, and Japan, to ensure their quality and to avoid any health hazards. In particular, the level of pyrogen must be controlled as it potentially causes life-threating septic shock. [1] [2] [3] [4] [5] Bacterial endotoxin, (also called lipopolysaccharide, LPS), of gram-negative bacteria is the pyrogen of main concern to the parenteral drugs in pharmaceutical factories as it is a common contaminant and shows powerful pyrogenicity. [1] [2] Bacterial endotoxins are detected and quantified by lysate reagents, which are prepared from amoebocyte extracts (limulus amoebocyte lysate, LAL) from a natural resource; horseshoe crab. [6] [7] [8] Lysate reagents are composed of three protease zymogens, factor C, factor B, and the proclotting enzyme, as well as a coagulogen to form the cascade reaction. 9) The test using limulus lysate reagents is called Bacterial Endotoxins Test (BET), and is filed in the pharmacopeias. [10] [11] [12] The reliance of the lysate reagents on a natural resource implies three issues. The first is Biological and Pharmaceutical Bulletin Advance Publication the potential decrease in the population of the horseshoe crab due to harvesting by commercial fishing to bait traps for eels and conch. [13] [14] [15] The second is the lot-to-lot variation of limulus lysate reagents possibly due to geographical and seasonal differences. [16] [17] [18] The third is a nonspecific reaction derived from an alternative factor G pathway in LAL, reacting with (1->3)-beta-D-glucan. 8, 9) This factor G pathway may lead to a false-positive test result.
To address these issues, some products have been marketed, including PyroGene and EndoZyme, which use recombinant factor C alone and a fluorogenic substrate. 19, 20) PyroSmart is characterized by three recombinant factors including factor C, factor B and the proclotting enzyme and a chromogenic substrate. 21) Several reports regarding evaluations of PyroGene have been published. 20, 22, 23) In these evaluations the equivalency of the endotoxin levels in some parenteral drugs by PyroGene and the current limulus lysate reagents was discussed. However, equivalency between all currently available recombinant reagent products and the existing limulus lysate reagents in measuring endotoxin levels in the many parenteral drugs listed in pharmacopeias has not been fully investigated.
In this report, the potencies of various rough and smooth forms of endotoxins from different bacterial strains using PyroSmart were compared against six lysate reagents. In addition, we assessed the performance of PyroSmart's analytical characteristics. Based on the results obtained, the applicability of the PyroSmart to BET is shown. The equivalency of measuring endotoxin with PyroSmart and current limulus lysate reagents is discussed. 
MATERIALS AND METHODS

Materials
Potencies of various endotoxins with lysate reagents and recombinant reagents
USPRSE was used as reference standard and was diluted to prepare a series of standard solutions of 0.1, 0.05, 0.025, 0.0125 and 0.00625 endotoxin unit (EU)/mL and a series of standard solutions of 50, 5, 0.5, 0.05 and 0.005 EU/mL for rate and onset time assay mode, respectively. Endotoxins derived from Escherichia coli O55:B5, E.coli O111:B4, E.coli O127:B8, E.coli O128:B12, E.coli J5, Shigella flexneri and Salmonella enterica, were dissolved into water. The endotoxins from E. coli F583 Rd2, S. minnesota R595 Re, S. typhrimrium, S. typhosa and Pseudomonas aeruginosa 10, were dissolved into 0.1%(v/v) triethylamine (TEA). Subsequently, the dissolved endotoxins were diluted with water for BET to obtain a two-fold or ten-fold dilution series for tests in the endotoxin assays with various reagents. The potency, EU/ng, of each dilution of endotoxins was calculated by dividing EU/mL by concentration, ng/mL at each dilution of endotoxins. The mean potencies of endotoxins were calculated by averaging the potencies of endotoxin dilutions within the range of the standard solutions.
Assessments of the analytical characteristics of the reagent We evaluated PyroSmart
with respect to analytical characteristics, accuracy, precision, specificity, quantitation limit, linearity, and range, which are required to be evaluated in quantitative tests for impurities' content in the ICH Q2 guideline. 24) We used both rate and onset time assay modes to assess the analytical characteristics of the recombinant chromogenic reagent. The acceptance criteria described in the Guideline on Bioanalytical Method (Ligand Binding Assay) Validation in
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Pharmaceutical Development, 25) which is used to evaluate measuring methods of analytes in a given biological matrix was referred since the ICH Q2 guideline as well as the Japanese Pharmacopoeia (JP), United States Pharmacopeia (USP), European Pharmacopoeia (EP), and their related guidelines do not describe any acceptance criteria on repeatability, intermediate precision, reproducibility, and quantitation limit. The specificity was assessed based on the reactivity of the reagent with BG, which is well-known as a false positive substance to lysate reagents. We assessed these analytical characteristics except for specificity by changing three factors, analyst, equipment, and reagent lot. In practice, two analysts used two microplate readers and three lots of the reagent to conduct independently a total of 12 measurements.
Linearity-For the rate assay, a series of JPRSE dilutions of 0.1, 0.05, 0.025, 0.0125, and 0.00625 EU/mL were prepared and then measured in six replicates with the reagent. For the onset time assay, a series of USPRSE dilutions of 50, 5, 0.5, 0.05, and 0.005 EU /mL were prepared and then measured in eight replicates with the reagent. According to the regression analysis, the correlation coefficients for the rate and onset time assay modes were determined based on the results of twelve measurements.
Accuracy-Accuracy was assessed by calculating the recoveries of endotoxin based on the average of concentrations of endotoxin that had been measured in six replicates and eight replicates according to the rate and onset time methods, respectively, at each concentration of endotoxin on the regression line in the twelve measurements.
Repeatability-The coefficient of variation (CV) was calculated based on the concentration of endotoxin that was measured at each endotoxin concentration on the regression line in the twelve measurements described in the section of linearity assessment according to the rate and onset time assay, respectively.
Intermediate precision-The standard deviation (SD) was calculated based on twelve measurements in the section of linearity assessment in the rate assay mode, while the SD was calculated from each logarithmically converted value of the endotoxin concentration on the regression line in the twelve measurements described in the section of linearity assessment in the onset time mode. The 90% confidence interval (CI) for CV was calculated according to the following equation: [(n -1) SD 2 /χ 2 (n -1, 0.05) ≤ σ 2 ≤ (n -1) SD 2 /χ 2 (n -1, 0.95)], where "σ" expresses the population standard deviation.
Reproducibility-Reproducibility was assessed in the onset time assay mode using a total of eighteen measured concentrations of endotoxin in two different laboratories consisting of the twelve measurements described in the section for linearity assessment and further six measurements in another institution, where one analyst measured three lots of the reagent with one microplate reader at two different days. Subsequently, SD was calculated from the abovementioned all eighteen measurements, and the 90% CI for the CV was calculated as described above. Furthermore, the eighteen endotoxin concentrations were converted logarithmically, and two-way repeated measures analysis of variance was made (variable 1: two institutions, variable 2: five concentrations of endotoxin).
Range-The range is the interval between the upper and lower concentration of endotoxin in the sample for which it has been demonstrated that the analytical procedure has acceptable levels of accuracy, precision (repeatability and intermediate precision), and linearity. 24) Quantification limit (QL)-In the rate assay mode QL was calculated based on the slope of the standard curve around QL and on SD of the absorbance change rates in the water for BET as the blank sample: (QL = 10 SD/slope). A series of JPRSE dilutions of 0.01, 0.005, 0.0025 and 0.00125 EU/mL were prepared. The series of JPRSE dilutions and blank sample were measured in five and ten replicates, respectively. Three measurements with three PyroSmart lots -a total of nine measurements -were conducted. The 95% CI for the mean of the QLs was calculated. In the onset time, QL was determined as a minimum concentration where the acceptance criteria were satisfied for both accuracy and precision among endotoxin concentrations described above. 
Specificity-To verify interference by (1->3)-beta-D-glucan (BG), two series of
RESULTS
Potency of endotoxins from different bacterial strains measured with PyroSmart
and limulus lysate reagents The equivalence of product performance between a recombinant chromogenic reagent, PyroSmart, and limulus lysate reagents was evaluated from potencies of the endotoxins from thirteen strains of gram-negative bacteria using either the rate or the onset time assay. These data are shown in Figure 1 . All potencies of thirteen endotoxins with PyroSmart fell in the range between 50% of minimum and 200 % of maximum of those tested with the three limulus lysate reagents. The endotoxins that were dissolved initially in TEA, specifically from E. coli strain F583 Rd2 and the S. minnesota strain R595 Re which has a short-sugar chain structure (rough form), showed relatively large reagent-to-reagent variability when compared with other endotoxins. On the other hand, the relative potencies of JPRSE with a long-sugar chain structure (smooth form) which had been well purified and dissolved in water for the BET were almost equivalent using PyroSmart and limulus lysate reagents. All of the CVs which were calculated from the potencies of Biological and Pharmaceutical Bulletin Advance Publication endotoxins with the three lots of PyroSmart were below 10%, except for Pseudomonas aeruginosa 10 (12.7%).
In addition, the potencies of endotoxins measured with two kinds of reagents were compared in regression analysis. The analysis was done after potencies were transformed logarithmically in nine combinations (combinations A to F, between PyroSmart and lysate reagents; combinations G to I, among lysate reagents; Table 1 , Supplement Figure 1 ). In the case of combination A (PyroSmart and Endospecy; both in the rate assay mode) and combination E (PyroSmart and Kinetic-QCL; both in the onset time assay mode) the 95% CI of the slope included "1", and the 95% CI for the y intercept included "0", indicating that the potencies of thirteen endotoxins that were measured with PyroSmart and lysate reagents in combinations A and E are statistically equivalent. In addition, the correlation coefficients in the combinations A and E were 0.936 and 0.947, respectively, showing good correlation in the two combinations. Table 2 shows the comparison of the acceptance criteria to the results generated by PyroSmart.
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Analytical characteristics of PyroSmart
Linearity -Typical standard curves for endotoxin quantitation obtained with PyroSmart in the rate and onset time assays are shown in Figure 2 . Both in the rate and onset time assays, the correlation coefficients calculated from all standard curves satisfied the acceptance criteria (|r| ≥ 0.980) that are described in the preparatory test of the BET.
Accuracy -In either the rate or onset time assay, the accuracy value, namely recovery, of added endotoxin satisfied the acceptance criteria for the test of interfering factors as described in the BET, i.e., 50-200%.
Precision -Repeatability, Intermediate precision and Reproducibility all satisfied their acceptance criteria as shown in Table 2 .
Range -The range was found to be 0.00625-0.1 EU /mL for the rate assay and 0.005-50 EU /mL for the onset time method.
Quantitation limit -In the rate assay mode, the mean of the quantitation limit was Biological and Pharmaceutical Bulletin Advance Publication 0.0012 EU /mL. The upper limit of the 95% CI for the endotoxin concentrations in the blank sample was 0.0002 EU /mL, while the lower limit of the 95% CI for the JPRSE 0.00125 EU/mL was 0.00126 EU /mL. Therefore, the ranges of endotoxin concentrations of in the blank sample and JPRSE did not overlap. Using onset time, both accuracy and precision at 0.005 EU/mL of endotoxin satisfied the acceptance criteria, indicating the lower limit of quantitation for the onset time method is 0.005 EU/mL.
Reactivity to (1->3)-beta-D-glucan (BG) -Regression analysis for the results of three lots with and without the addition of BG was conducted ( Figure 3) . The 95% CI for the y-intercept and the slope of the regression formula with the three lots contained "0" and "1", respectively, indicating there is no statistical difference between the endotoxin concentrations with and without BG.
Ability to assess endotoxin in the presence of injectable drugs -We examined the interference to the test by examining the recovery of endotoxins added to 109 out of 118 available injectable drugs listed in the monographs of Japanese Pharmacopoeia. In both the rate and onset time assays, all minimum dilution factors expressed as NIDs of the 109 injectable drugs, which were measured with PyroSmart, were smaller than the MVDs of respective drugs ( Table 3 ). NIDs of 109 injectable drugs which were measured with three lysate reagents were also smaller than their MVDs.
Comparison between PyroSmart and limulus lysate reagents
Potencies of endotoxins -The potencies of three typical types of endotoxins were measured with the three recombinant reagents including PyroSmart and six lysate reagents produced from the horseshoe crab ( Figure 4 ). There was no significant difference based on F-test and t-test (P=0.05) between the recombinant reagents (generating four data sets) and lysate reagents (generating six data sets). Table 4 .
The variation in the NIDs within the three recombinant reagents is similar to that within five lysate reagents. All three recombinant reagents show little lot-to-lot variations of endotoxin-recoveries in all twenty-seven drugs. In contrast, four out of five lysate reagents showed lot-to-lot variations equal to or larger than 8-fold in seven of twenty-seven drugs examined.
DISCUSSION
As reported in literature, 22, 27-32) endotoxins from different bacterial strains showed highly varying potencies. This is due to their differing structures of the lipid A moiety and polysaccharide length (1.87 EU/ng of E. coli J5 versus 118 EU/ng of E. coli F583 Rd2) ( Figure 1 ).
The variance of the potency of each endotoxin among lysate reagents is maximally 5.5-fold and minimally 1.7-fold. On the other hand, all potencies of the thirteen endotoxins when tested with PyroSmart fell in the range between 50 of minimum and 200 % of maximum of those with the three lysate reagents. In addition, potencies except for that of S. typhimurium obtained with PyroSmart fell in the range of the mean+/-3SD of the potencies with the three lysate reagents, suggesting again that the reactivity of PyroSmart to each endotoxin is almost equal to those of the three lysate reagents. Figure 4 also shows no significant differences in reactivities of the three recombinant reagents and the six lysate reagents.
All analytical characteristics in method validation of the PyroSmart satisfied the acceptance criteria (Table 2) . Thus, the recombinant chromogenic reagent, PyroSmart can be applicable as an alternative to the BET in the pharmacopeias.
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All minimum dilution factors expressed as NIDs of the 109 injectable drugs measured with PyroSmart were smaller than the MVDs of respective drugs (Table 3 ). In further experiment, the three recombinant reagents showed a similar susceptibility to interference in 27 drugs as the five lysate reagents (Table 4 ). Moreover, the lot-to-lot variation of susceptibility in the assays with the recombinant reagents was equal to or smaller than those with lysate reagents. Of the three recombinant reagents, only PyroSmart was able to detect endotoxin in the drug, Heparin Calcium, which strongly inhibited the detection by other recombinant reagents. The difference in susceptibility to the interference derived from Heparin Calcium between PyroSmart and the two recombinant factor C reagents may be attributable to the components, other than factor C, contained in PyroSmart. Heparin is known to interact with factors C and B, 33, 34) therefore Heparin Calcium may reduce the quantity of recombinant factor C available for endotoxin in PyroGene and EndoZyme also in PyroSmart. However factor B is also reported to be involved in endotoxin recognition as well as in signal transduction from the upstream factor C. 35) Thus, the presence of factor B in PyroSmart may mitigate the strong inhibition by Heparin Calcium.
It is also reported that the recombinant factor C in PyroSmart produced from mammalian cells is less susceptible to interference by some substances than the recombinant products only containing factor C from insect cells or factor C purified from horseshoe crab. 21) In conclusion, an endotoxin assay using recombinant reagents can be an effective alternative assay for the Bacterial Endotoxins Test in the pharmacopeias. It would resolve the inconsistencies in test results caused by lot-to-lot variance of the lysate reagents and contribute to the conservation of the horseshoe crab. 
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